Community-acquired pneumonia

New England Journal of Medicine

Volumn 370, Issue 6, 2014, Pages 543-551

  Wunderink, Richard G ^a   Waterer, Grant W ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NITROGEN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SODIUM; UREA; ANTIINFECTIVE AGENT;

AGED; ALZHEIMER DISEASE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING RATE; CASE REPORT; CLINICAL DECISION MAKING; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; COUGHING; CRACKLE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; EMERGENCY WARD; FEMALE; FEVER; GRAM NEGATIVE INFECTION; HEALTH CARE ASSOCIATED PNEUMONIA; HEART RATE; HUMAN; INFECTION CONTROL; INFECTION RISK; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; OXYGEN SATURATION; PATIENT CARE; PATIENT TRANSPORT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SODIUM BLOOD LEVEL; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT PLANNING; UREA NITROGEN BLOOD LEVEL; COMMUNICABLE DISEASE; HOSPITALIZATION; LUNG; MICROBIOLOGY; PNEUMONIA; RADIOGRAPHY; REVIEW;

AGED; ALZHEIMER DISEASE; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITALIZATION; HUMANS; LUNG; PNEUMONIA; PRACTICE GUIDELINES AS TOPIC;

EID: 84893609243     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1214869     Document Type: Article

References (48)

1. The top 10 causes of death. Geneva: World Health Organization, 2013 (http://www.who.int/mediacentre/factsheets/fs310/en/index.html).
2. Murphy SL, Xu J, Kochanek KD. Deaths: preliminary data for 2010. Natl Vital Stat Rep 2012;60:1-51.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10. (Pubitemid 32641789)
4. Brancati FL, Chow JW, Wagener MM, Vacarello SJ, Yu VL. Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet 1993;342:30-3. (Pubitemid 23183921)
5. Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004;169:910-4. (Pubitemid 38457316)
6. Yende S, Angus DC, Ali IS, et al. Influence of comorbid conditions on longterm mortality after pneumonia in older people. J Am Geriatr Soc 2007;55:518-25. (Pubitemid 46496572)
7. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002;166:717-23. (Pubitemid 34971856)
8. Wilson KC, Schünemann HJ. An appraisal of the evidence underlying performance measures for community-acquired pneumonia. Am J Respir Crit Care Med 2011;183:1454-62.
9. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006;130:11-5. (Pubitemid 44116836)
10. Albaum MN, Hill LC, Murphy M, et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. Chest 1996;110:343-50. (Pubitemid 26269258)
11. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013;369:155-63.
12. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005;40:1288-97. (Pubitemid 40570238)
13. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:Suppl 2:S27-S72. (Pubitemid 46290553)
14. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-72.
15. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003;123:1503-11. (Pubitemid 36549769)
16. Capelastegui A, España PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004;39:955-63. (Pubitemid 39313450)
17. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001;110:451-7.
18. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007;131:466-73. (Pubitemid 46280407)
19. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2013 October 23 (Epub ahead of print).
20. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44. (Pubitemid 38392978)
21. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4. (Pubitemid 28016230)
22. Polgreen PM, Chen YY, Cavanaugh JE, et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol 2007;28:212-4. (Pubitemid 46374165)
23. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865-9. (Pubitemid 46981647)
24. Barlow G, Nathwani D, Williams F, et al. Reducing door-to-antibiotic time in community-acquired pneumonia: controlled before-and-after evaluation and cost-effectiveness analysis. Thorax 2007;62:67-74. (Pubitemid 46110371)
25. Pines JM, Isserman JA, Hinfey PB. The measurement of time to first antibiotic dose for pneumonia in the emergency department: a white paper and position statement prepared for the American Academy of Emergency Medicine. J Emerg Med 2009;37:335-40.
26. Lim HF, Phua J, Mukhopadhyay A, et al. IDSA/ATS minor criteria aided pre-ICU resuscitation in severe community-acquired pneumonia. Eur Respir J 2013 October 31 (Epub ahead of print).
27. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96. (Pubitemid 43810035)
28. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
29. Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013;188:985-95.
30. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-62. [Erratum, Chest 2006;129:831.] (Pubitemid 43062645)
31. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and communityacquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007;51:3568-73. (Pubitemid 47519345)
32. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007;45:315-21. (Pubitemid 47101027)
33. Sicot N, Khanafer N, Meyssonnier V, et al. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia: results of a prospective observational study. Clin Microbiol Infect 2013;19:E142-E148.
34. Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005;143:881-94. (Pubitemid 46205946)
35. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. (Pubitemid 27044625)
36. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. (Pubitemid 36560938)
37. Renaud B, Santin A, Coma E, et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009;37:2867-74.
38. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010;137:552-7.
39. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47:375-84. (Pubitemid 352009359)
40. Renaud B, Labarère J, Coma E, et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care 2009;13:R54.
41. España PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006;174:1249-56. (Pubitemid 44924826)
42. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
43. Labelle AJ, Arnold H, Reichley RM, Micek ST, Kollef MH. A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest 2010;137:1130-7.
44. Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011;53:107-13.
45. Kett DH, Cano E, Quartin AA, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011;11:181-9.
46. Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 2011;38:878-87.
47. El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis 2004;39:474-80. (Pubitemid 39120921)
48. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections: summary. Clin Microbiol Infect 2011;17:Suppl 6:1-24.